What is Masimo Corporation's earnings per share (EPS)?

Masimo Corporation (MASI) reported diluted earnings per share of -$2.80 for fiscal year 2025. This represents a 50.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Masimo Corporation (MASI) Financials

MASI

Trailing 12 months to April 4, 2026

Revenue $1.6B +9.2% YoY

Net Income $76.3M +115.4% YoY

EPS (Diluted) $1.40 +115.3% YoY

Free Cash Flow $210.9M +28.5% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2027, ended Apr 4, 2026 Reported May 5, 2026 Currency USD FYE January

Newest figures come from the 10-Q for Q1 FY2027, filed May 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MASI SEC filings page.

Masimo Corporation (MASI) reported $1.6B in revenue over the twelve months to Apr 4, 2026, up 9.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MASI FY2025 2026-10-04

The business restored operating profitability and cash generation in FY2025, but reported net income remains negative while the balance sheet is smaller.

FY2025 paired a 20.3% operating margin with $217.8M of operating cash flow, showing the recovery reached both the income statement and cash engine. Yet a $151.5M net loss alongside $198.4M of free cash flow means cash performance is currently more informative than bottom-line earnings, which are being affected materially below operating profit.

Gross margin rose from 56.9% in FY2024 to 61.9% in FY2025, so the improvement was not merely a result of selling more. Operating margin also climbed from 4.5% to 20.3% while selling, general and administrative expense fell to $506M, pointing to a combination of better product economics and tighter operating cost absorption.

Total liabilities fell from $1.6B in FY2024 to $977.7M in FY2025, reducing the absolute financing burden. However, debt-to-equity remained about 0.7x, so the smaller balance sheet did not eliminate leverage; the stronger liquidity profile should be viewed alongside that continuing capital structure.

Financial Health Signals

Financial Health Score 66/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Masimo Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Masimo Corporation has an operating margin of 20.3%, meaning the company retains $20 of operating profit per $100 of revenue. This strong profitability earns a score of 77/100, reflecting efficient cost management and pricing power. This is up from 4.5% the prior year.

Growth

Masimo Corporation's revenue grew 9.4% year-over-year to $1.5B, a solid pace of expansion. This earns a growth score of 64/100.

Leverage

Masimo Corporation has a moderate D/E ratio of 0.72. This balance of debt and equity financing earns a leverage score of 46/100.

Liquidity

With a current ratio of 2.49, Masimo Corporation holds $2.49 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 71/100.

Cash Flow

Masimo Corporation converts 13.0% of revenue into free cash flow ($198.4M). This strong cash generation earns a score of 69/100.

Returns

Masimo Corporation posts a -21.0% return on equity (ROE), meaning it loses $21 for every $100 of shareholders' equity. This results in a returns score of 69/100. This is up from -29.0% the prior year.

Altman Z-Score Safe

8.78

Masimo Corporation scores 8.78, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($9.4B) relative to total liabilities ($977.7M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

7/9

Masimo Corporation passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

N/A

Masimo Corporation reported a net loss of $151.5M while generating $217.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage Safe

9.34x

Masimo Corporation earns $9.34 in operating income for every $1 of interest expense ($310.0M vs $33.2M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$403.6M

YoY+8.5%

QoQ-2.2%

Masimo Corporation generated $403.6M in revenue in Q1 2027. This represents an increase of 8.5% from the same quarter a year earlier. Against the prior quarter it is down 2.2%.

EBITDA

$85.5M

YoY-1.3%

QoQ-15.8%

Masimo Corporation's EBITDA was $85.5M in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 1.3% from the same quarter a year earlier. Against the prior quarter it is down 15.8%.

Net Income

$57.1M

YoY+133.5%

QoQ-16.4%

Masimo Corporation reported $57.1M in net income in Q1 2027. This represents an increase of 133.5% from the same quarter a year earlier. Against the prior quarter it is down 16.4%.

EPS (Diluted)

$1.09

YoY+134.9%

QoQ-9.9%

5Y CAGR+3.4%

10Y CAGR+7.5%

Masimo Corporation earned $1.09 per diluted share (EPS) in Q1 2027. This represents an increase of 134.9% from the same quarter a year earlier. Against the prior quarter it is down 9.9%.

Cash & Balance Sheet

Free Cash Flow

$41.0M

YoY+43.9%

QoQ-23.2%

5Y CAGR-4.0%

10Y CAGR+11.8%

Masimo Corporation generated $41.0M in free cash flow in Q1 2027, representing cash available after capex. This represents an increase of 43.9% from the same quarter a year earlier. Against the prior quarter it is down 23.2%.

Cash & Debt

$124.6M

YoY-4.7%

QoQ-18.2%

5Y CAGR-25.7%

10Y CAGR-1.2%

Masimo Corporation held $124.6M in cash against $445.7M in long-term debt as of Q1 2027.

Shares Outstanding

52M

YoY-3.4%

QoQ+0.3%

5Y CAGR-1.0%

10Y CAGR+0.7%

Masimo Corporation had 52M shares outstanding in Q1 2027. This represents a decrease of 3.4% from the same quarter a year earlier. Against the prior quarter it is up 0.3%.

Dividends Per Share

Not reported for Q1 2027.

Margins & Returns

Gross Margin

62.1%

YoY-0.8pp

QoQ+2.2pp

Masimo Corporation's gross margin was 62.1% in Q1 2027, indicating the percentage of revenue retained after direct costs. This is down 0.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.2 percentage points.

Operating Margin

19.2%

YoY-1.8pp

QoQ-1.2pp

Masimo Corporation's operating margin was 19.2% in Q1 2027, reflecting core business profitability. This is down 1.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.2 percentage points.

Net Margin

14.1%

YoY+60.0pp

QoQ-2.4pp

Masimo Corporation's net profit margin was 14.1% in Q1 2027, showing the share of revenue converted to profit. This is up 60.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.4 percentage points.

Return on Equity

7.2%

YoY+25.3pp

QoQ-2.2pp

Masimo Corporation's ROE was 7.2% in Q1 2027, measuring profit generated per dollar of shareholder equity. This is up 25.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.2 percentage points.

Capital Allocation

R&D Spending

$30.0M

YoY-11.5%

QoQ-6.5%

Masimo Corporation invested $30.0M in research and development in Q1 2027. This represents a decrease of 11.5% from the same quarter a year earlier. Against the prior quarter it is down 6.5%.

Capital Expenditures

$4.3M

YoY+65.4%

QoQ-39.4%

5Y CAGR-13.5%

10Y CAGR-2.2%

Masimo Corporation invested $4.3M in capex in Q1 2027, funding long-term assets and infrastructure. This represents an increase of 65.4% from the same quarter a year earlier. Against the prior quarter it is down 39.4%.

Share Buybacks

Not reported for Q1 2027.

MASI Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MASI quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$1.6B	$1.5B+9.4%	$1.4B+9.4%	$1.3B-37.3%	$2.0B+64.3%	$1.2B+8.3%	$1.1B+22.0%	$937.8M+9.3%	$858.3M+8.6%	$790.2M+10.9%	$712.9M+13.1%	$630.1M+7.4%	$586.6M+7.2%	$547.2M+11.0%	$493.2M+12.4%	$439.0M
Cost of Revenue	$596.5M	$581.7M-3.2%	$600.9M+17.8%	$509.9M-47.8%	$977.0M+126.8%	$430.8M+7.5%	$400.7M+29.8%	$308.7M+8.9%	$283.4M+5.7%	$268.2M+14.3%	$234.6M+6.6%	$220.1M+12.4%	$195.9M+4.0%	$188.4M+12.8%	$167.0M+15.3%	$144.9M
Gross Profit	$962.0M	$945.2M+19.0%	$794.3M+3.7%	$765.6M-27.7%	$1.1B+31.0%	$808.4M+8.8%	$743.0M+18.1%	$629.2M+9.4%	$574.9M+10.1%	$522.0M+9.1%	$478.3M+16.7%	$410.0M+4.9%	$390.8M+8.9%	$358.8M+10.0%	$326.3M+10.9%	$294.1M
R&D Expenses	$122.5M	$126.4M-30.6%	$182.2M+39.6%	$130.5M-31.8%	$191.4M+39.5%	$137.2M+15.6%	$118.7M+27.2%	$93.3M+15.2%	$81.0M+24.2%	$65.2M+13.1%	$57.7M+1.9%	$56.6M+0.1%	$56.6M+1.7%	$55.6M+18.2%	$47.1M+22.6%	$38.4M
SG&A Expenses	$530.0M	$506.0M-7.8%	$548.6M+21.6%	$451.3M-31.4%	$657.4M+66.3%	$395.4M+7.2%	$369.0M+17.3%	$314.7M+10.2%	$285.4M+4.5%	$273.0M+7.2%	$254.7M+0.8%	$252.7M+4.9%	$241.0M+11.9%	$215.5M+11.1%	$193.9M+14.6%	$169.2M
Operating Income	$309.4M	$310.0M+392.1%	$63.0M-62.0%	$166.0M-21.0%	$210.0M-23.9%	$275.8M+7.8%	$255.8M+15.6%	$221.2M+6.3%	$208.0M+13.2%	$183.8M-57.8%	$435.9M+262.5%	$120.3M+16.2%	$103.5M+29.9%	$79.7M-6.5%	$85.2M-1.5%	$86.5M
EBITDA	N/A	$348.8M+212.8%	$111.5M-45.6%	$204.9M-40.8%	$346.1M+11.1%	$311.4M+9.2%	$285.1M+16.5%	$244.7M+6.8%	$229.2M+12.4%	$203.8M-55.0%	$452.8M+233.1%	$135.9M+16.9%	$116.3M+27.6%	$91.1M-3.7%	$94.6M+0.8%	$93.9M
Interest Expense	$30.5M	$33.2M-19.4%	$41.2M-18.1%	$50.3M+95.7%	$25.7M+8466.7%	$300K0.0%	$300K-8.5%	$328K-53.5%	$706K+4.1%	$678K-79.2%	$3.3M-6.9%	$3.5M+483.3%	$600K+500.0%	$100K0.0%	$100K	N/A
Income Tax	$58.7M	$64.9M+1058.9%	$5.6M+5.7%	$5.3M-89.4%	$49.9M+11.4%	$44.8M+91.5%	$23.4M-38.3%	$38.0M+87.6%	$20.2M-66.8%	$61.0M-50.2%	$122.4M+251.3%	$34.8M+25.9%	$27.7M+38.4%	$20.0M-8.6%	$21.9M-2.6%	$22.5M
Net Income	$76.3M	-$151.5M+50.3%	-$304.9M-474.1%	$81.5M-43.2%	$143.5M-37.5%	$229.6M-4.5%	$240.3M+22.5%	$196.2M+1.4%	$193.5M+55.1%	$124.8M-59.9%	$311.1M+273.5%	$83.3M+14.9%	$72.5M+24.2%	$58.4M-6.2%	$62.3M-2.2%	$63.7M
EPS (Basic)	N/A	-$2.83+50.5%	-$5.72-471.4%	$1.54-42.5%	$2.68-35.6%	$4.16-5.2%	$4.39+19.6%	$3.67-0.8%	$3.70+52.9%	$2.42-61.5%	$6.28+287.7%	$1.62+21.8%	$1.33+29.1%	$1.03-4.6%	$1.08+0.9%	$1.07
EPS (Diluted)	$1.40	-$2.80+50.0%	-$5.60-470.9%	$1.51-41.9%	$2.60-34.7%	$3.98-3.9%	$4.14+20.3%	$3.44-0.3%	$3.45+54.7%	$2.23-61.9%	$5.85+277.4%	$1.55+19.2%	$1.30+27.5%	$1.02-4.7%	$1.07+1.9%	$1.05
Diluted Shares (Avg)	N/A	54M-0.4%	54M+0.6%	54M-2.0%	55M-4.3%	58M-0.5%	58M+1.6%	57M+1.9%	56M+0.3%	56M+5.0%	53M-1.0%	54M-3.4%	56M-3.3%	57M-1.5%	58M-4.1%	61M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Revenue	$403.6M+8.5%	$412.5M+12.0%	$371.5M+8.2%	$370.9M+7.9%	$372.0M+9.5%	$368.4M	$343.3M-28.3%	$343.9M-24.5%
Cost of Revenue	$152.8M+10.7%	$165.2M-17.4%	$140.9M+7.4%	$137.6M+0.7%	$138.0M+3.8%	$200.1M	$131.2M-46.3%	$136.6M-41.6%
Gross Profit	$250.8M+7.2%	$247.3M+46.9%	$230.6M+8.7%	$233.3M+12.5%	$234.0M+13.3%	$168.3M	$212.1M-9.7%	$207.3M-6.3%
R&D Expenses	$30.0M-11.5%	$32.1M-52.8%	$30.5M-18.2%	$29.9M-23.5%	$33.9M-10.3%	$68.0M	$37.3M-19.8%	$39.1M-2.7%
SG&A Expenses	$143.4M+20.1%	$131.3M-22.8%	$116.4M-14.8%	$138.9M+10.0%	$119.4M+3.2%	$170.0M	$136.6M-12.5%	$126.3M-16.7%
Operating Income	$77.4M-0.8%	$83.9M+219.5%	$83.6M+118.8%	$64.5M+53.9%	$78.0M+46.9%	-$70.2M	$38.2M+51.6%	$41.9M+43.0%
EBITDA	$85.5M-1.3%	$101.5M+237.2%	$89.8M+50.9%	$70.9M+12.7%	$86.6M+37.2%	-$74.0M	$59.5M+19.7%	$62.9M+15.6%
Interest Expense	$6.1M-30.7%	$7.4M-14.9%	$8.8M-11.1%	$8.2M-22.6%	$8.8M-26.7%	$8.7M	$9.9M-22.7%	$10.6M-10.2%
Income Tax	$15.0M-29.2%	$12.0M+181.6%	$21.2M+332.7%	$10.5M+75.0%	$21.2M+125.5%	-$14.7M	$4.9M+44.1%	$6.0M-34.1%
Net Income	$57.1M+133.5%	$68.3M+119.5%	-$100.4M-1124.5%	$51.3M+220.6%	-$170.7M-1003.2%	-$349.6M	$9.8M-7.5%	$16.0M+1.9%
EPS (Basic)	$1.10+134.7%	$1.23+118.8%	-$1.86-1078.9%	$0.95+216.7%	-$3.17-980.6%	-$6.56-1125.0%	$0.19-5.0%	$0.300.0%
EPS (Diluted)	$1.09+134.9%	$1.21+118.5%	-$1.84-1122.2%	$0.94+213.3%	-$3.12-991.4%	-$6.54-1138.1%	$0.18-10.0%	$0.30+3.4%
Diluted Shares (Avg)	53M-4.0%	N/A	54M+0.2%	55M+0.9%	55M+1.1%	N/A	54M+0.7%	54M-0.2%

MASI Balance Sheet

MASI quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$1.7B-35.3%	$2.6B-13.7%	$3.0B-5.3%	$3.2B+70.1%	$1.9B+10.2%	$1.7B+22.7%	$1.4B+20.9%	$1.2B+27.5%	$905.4M+10.3%	$820.5M+36.4%	$601.7M+6.5%	$565.0M+28.8%	$438.7M+17.1%	$374.7M+2.3%	$366.1M
Current Assets	$926.0M-24.5%	$1.2B-0.5%	$1.2B-5.9%	$1.3B+5.7%	$1.2B+12.5%	$1.1B+10.6%	$996.1M+26.2%	$789.3M+41.0%	$559.7M+10.3%	$507.2M+69.6%	$299.1M+0.7%	$297.1M+9.3%	$271.8M+23.9%	$219.3M-16.6%	$262.9M
Cash & Equivalents	$152.3M+23.2%	$123.6M-24.2%	$163.0M-19.7%	$202.9M-72.8%	$745.3M+16.2%	$641.4M+13.0%	$567.7M+2.8%	$552.5M+75.2%	$315.3M+3.0%	$306.0M+131.2%	$132.3M-1.6%	$134.5M+40.8%	$95.5M+33.4%	$71.6M-44.9%	$129.9M
Short-Term Investments	$0	$0	$0	$0	$0	$0-100.0%	$120.0M	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$380.3M+29.0%	$294.8M-45.9%	$545.0M+8.8%	$501.0M+148.8%	$201.4M-6.7%	$216.0M+86.4%	$115.9M+22.3%	$94.7M+2.7%	$92.3M+27.2%	$72.5M+16.9%	$62.0M-11.0%	$69.7M+22.7%	$56.8M+20.0%	$47.4M+3.1%	$45.9M
Accounts Receivable	$275.8M-2.6%	$283.2M+26.3%	$224.2M-49.7%	$445.9M+122.1%	$200.8M+42.1%	$141.3M+6.7%	$132.4M+20.8%	$109.6M-7.5%	$118.5M+16.6%	$101.7M+25.6%	$81.0M+14.0%	$71.0M-7.5%	$76.8M+13.0%	$67.9M+19.1%	$57.0M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$101.0M+4.4%	$96.7M-1.9%	$98.6M-77.9%	$445.4M+344.1%	$100.3M-2.8%	$103.2M+361.7%	$22.4M-4.1%	$23.3M+13.0%	$20.6M+4.2%	$19.8M-3.0%	$20.4M-2.8%	$21.0M-8.0%	$22.8M-0.1%	$22.8M+4994.6%	$448K
Total Liabilities	$977.7M-37.9%	$1.6B-6.1%	$1.7B-10.4%	$1.9B+455.7%	$336.8M+10.5%	$304.9M+33.6%	$228.3M+22.9%	$185.8M+2.4%	$181.4M-30.3%	$260.3M-20.2%	$326.0M+26.7%	$257.3M+129.2%	$112.3M+13.4%	$99.0M+14.5%	$86.4M
Current Liabilities	$371.6M-39.8%	$617.7M+9.6%	$563.8M-10.5%	$630.0M+135.3%	$267.7M+14.5%	$233.8M+35.8%	$172.2M+17.5%	$146.6M+13.0%	$129.7M-41.2%	$220.4M+66.1%	$132.6M+7.1%	$123.9M+19.4%	$103.8M+15.9%	$89.5M+17.9%	$76.0M
Non-Current Liabilities	$606.1M-36.6%	$956.1M-14.1%	$1.1B-10.4%	$1.2B+1697.0%	$69.1M-2.8%	$71.1M+26.8%	$56.0M+43.0%	$39.2M-24.3%	$51.8M+29.6%	$39.9M-79.4%	$193.4M+45.0%	$133.4M+1474.4%	$8.5M-10.4%	$9.5M-9.8%	$10.5M
Long-Term Debt	$518.0M-27.5%	$714.3M-18.1%	$871.7M-7.4%	$941.6M	$0	N/A	N/A	N/A	N/A	$0-100.0%	$185.1M+47.9%	$125.1M+55520.0%	$225K	N/A	N/A
Total Equity	$721.2M-31.4%	$1.1B-22.9%	$1.4B+1.9%	$1.3B-13.6%	$1.6B+10.1%	$1.4B+20.5%	$1.2B+20.5%	$969.1M+33.8%	$724.0M+29.2%	$560.2M+103.4%	$275.4M-10.0%	$306.0M-6.3%	$326.5M+19.6%	$273.1M-1.4%	$276.8M
Retained Earnings	$1.3B-10.2%	$1.5B-17.0%	$1.8B+4.8%	$1.7B+9.1%	$1.6B+17.1%	$1.3B+21.9%	$1.1B+18.2%	$931.1M+26.2%	$738.0M+25.2%	$589.2M+104.2%	$288.6M+40.6%	$205.3M+54.6%	$132.7M+78.5%	$74.4M+7.2%	$69.4M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Total Assets	$1.6B-28.4%	$1.7B-35.3%	$1.8B-41.1%	$2.4B-17.0%	$2.3B-22.5%	$2.6B-13.7%	$3.1B+3.1%	$2.9B-3.9%
Current Assets	$870.5M-26.5%	$926.0M-24.5%	$1.0B-18.1%	$1.3B+11.2%	$1.2B+1.6%	$1.2B-0.5%	$1.3B+3.4%	$1.1B-5.5%
Cash & Equivalents	$124.6M-4.7%	$152.3M+23.2%	$312.3M+97.0%	$149.6M+15.4%	$130.8M-17.0%	$123.6M-24.2%	$158.5M+27.4%	$129.6M-14.0%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$400.0M+32.8%	$380.3M+29.0%	$338.6M-40.6%	$318.5M-37.9%	$301.2M-40.5%	$294.8M-45.9%	$569.9M-2.5%	$513.0M-5.5%
Accounts Receivable	$238.7M	$275.8M-2.6%	N/A	N/A	N/A	$283.2M+26.3%	$371.0M+4.0%	$337.7M-3.2%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$100.9M+2.6%	$101.0M+4.4%	$100.8M-75.6%	$100.9M-74.1%	$98.3M-75.2%	$96.7M-1.9%	$412.5M+3.1%	$389.0M-5.3%
Total Liabilities	$853.8M-36.6%	$977.7M-37.9%	$1.0B-38.0%	$1.4B-10.8%	$1.3B-15.4%	$1.6B-6.1%	$1.6B-5.6%	$1.5B-10.4%
Current Liabilities	$325.4M-40.5%	$371.6M-39.8%	$369.7M-42.0%	$592.1M+8.4%	$546.5M+8.4%	$617.7M+9.6%	$637.6M+10.2%	$546.2M-4.5%
Non-Current Liabilities	$528.4M-34.0%	$606.1M-36.6%	$637.8M-35.4%	$767.7M-21.6%	$800.2M-26.5%	$956.1M-14.1%	$987.0M-13.5%	$978.9M-13.4%
Long-Term Debt	$445.7M-29.9%	$518.0M-27.5%	$559.1M-23.7%	$598.7M-19.8%	$636.0M-24.4%	$714.3M-18.1%	$733.2M-19.4%	$746.5M-16.0%
Total Equity	$788.9M-16.6%	$721.2M-31.4%	$810.0M-44.6%	$1.0B-23.8%	$946.4M-30.7%	$1.1B-22.9%	$1.5B+14.7%	$1.4B+4.6%
Retained Earnings	$1.4B+5.8%	$1.3B-10.2%	$1.3B-30.9%	$1.4B-25.1%	$1.3B-27.2%	$1.5B-17.0%	$1.8B+4.5%	$1.8B+4.5%

MASI Cash Flow Statement

MASI quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$232.0M	$217.8M+10.9%	$196.4M+108.7%	$94.1M+220.1%	$29.4M-88.9%	$264.6M+25.3%	$211.1M-4.8%	$221.6M-7.5%	$239.5M+327.3%	$56.1M-86.6%	$419.1M+257.6%	$117.2M+22.6%	$95.6M+73.5%	$55.1M-26.6%	$75.1M-4.9%	$79.0M
Depreciation & Amortization	N/A	$38.8M-20.0%	$48.5M+24.7%	$38.9M-71.4%	$136.1M+282.3%	$35.6M+21.5%	$29.3M+24.7%	$23.5M+11.2%	$21.1M+5.3%	$20.1M+19.3%	$16.8M+7.2%	$15.7M+22.4%	$12.8M+12.2%	$11.4M+21.9%	$9.4M+27.6%	$7.3M
Stock-Based Compensation	N/A	$35.8M-0.8%	$36.1M+491.8%	$6.1M-87.2%	$47.7M+6.7%	$44.7M+5.9%	$42.2M+7.6%	$39.2M+43.1%	$27.4M+59.5%	$17.2M+37.5%	$12.5M+15.5%	$10.8M-1.6%	$11.0M-5.7%	$11.7M-17.2%	$14.1M+3.1%	$13.7M
Capital Expenditures	$21.1M	$19.4M-8.1%	$21.1M-45.1%	$38.4M-27.3%	$52.8M+107.1%	$25.5M-64.8%	$72.5M+6.0%	$68.4M+299.2%	$17.1M-60.8%	$43.7M+121.7%	$19.7M-60.9%	$50.4M-32.9%	$75.1M+696.1%	$9.4M-10.4%	$10.5M+108.0%	$5.1M
Free Cash Flow	$210.9M	$198.4M+13.2%	$175.3M+214.7%	$55.7M+338.0%	-$23.4M-109.8%	$239.1M+72.5%	$138.6M-9.6%	$153.3M-31.1%	$222.4M+1696.7%	$12.4M-96.9%	$399.4M+497.8%	$66.8M+225.1%	$20.6M-55.0%	$45.7M-29.3%	$64.6M-12.6%	$73.9M
Investing Cash Flow	$260.2M	$275.1M+637.3%	-$51.2M+36.9%	-$81.2M+92.3%	-$1.1B-2720.5%	-$37.5M+54.7%	-$82.8M+58.1%	-$197.7M-655.9%	-$26.2M+45.4%	-$47.9M-89.3%	-$25.3M+53.6%	-$54.6M+30.9%	-$79.0M-472.1%	-$13.8M+73.2%	-$51.6M-587.0%	-$7.5M
Financing Cash Flow	-$543.1M	-$520.7M-314.6%	-$125.6M-120.0%	-$57.1M-111.0%	$520.4M+525.2%	-$122.4M-125.4%	-$54.3M-481.4%	-$9.3M-136.2%	$25.8M+723.0%	-$4.1M+98.1%	-$216.6M-249.0%	-$62.1M-333.0%	$26.6M+248.5%	-$17.9M+78.1%	-$82.1M-172.2%	-$30.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$57.3M	$0
Share Buybacks	N/A	$363.7M	$0	$0-100.0%	$401.5M+211.5%	$128.9M+16.7%	$110.5M+194.2%	$37.6M+103.2%	$18.5M-72.1%	$66.3M-2.9%	$68.2M-54.6%	$150.2M+46.6%	$102.5M+417.7%	$19.8M-24.7%	$26.3M-27.4%	$36.2M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Operating Cash Flow	$45.3M+45.7%	$60.5M+19.8%	$56.8M+121.9%	$69.4M-6.8%	$31.1M-32.1%	$50.5M-34.5%	$25.6M+465.7%	$74.5M+215.7%
Depreciation & Amortization	$8.1M-5.8%	$13.6M-23.6%	$6.2M-70.9%	$6.4M-69.5%	$8.6M-14.0%	$17.8M+148.2%	$21.3M-13.1%	$21.0M-16.3%
Stock-Based Compensation	$8.9M-2.2%	N/A	N/A	N/A	$9.1M+4.6%	N/A	N/A	N/A
Capital Expenditures	$4.3M+65.4%	$7.1M+14.5%	$5.9M+13.5%	$3.8M+5.6%	$2.6M-57.4%	$6.2M+17.0%	$5.2M-59.1%	$3.6M-69.7%
Free Cash Flow	$41.0M+43.9%	$53.4M+20.5%	$50.9M+149.5%	$65.6M-7.5%	$28.5M-28.2%	$44.3M-38.3%	$20.4M+203.6%	$70.9M+506.0%
Investing Cash Flow	-$4.2M-139.3%	-$8.7M+47.3%	$282.3M+2191.1%	-$9.2M-300.0%	$10.7M+156.6%	-$16.5M+34.8%	-$13.5M+39.7%	-$2.3M+89.7%
Financing Cash Flow	-$70.2M-46.9%	-$214.6M-3201.5%	-$218.4M-13550.0%	-$39.9M+56.2%	-$47.8M-80.4%	-$6.5M+82.1%	-$1.6M-108.3%	-$91.0M-1757.1%
Share Buybacks	N/A	$186.7M	$163.3M	N/A	N/A	$0	$0	N/A

Not reported in any period shown, so not listed: Dividends Paid.

MASI Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MASI quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	61.9%+5.0pp	56.9%-3.1pp	60.0%+8.0pp	52.0%-13.2pp	65.2%+0.3pp	65.0%-2.1pp	67.1%+0.1pp	67.0%+0.9pp	66.1%-1.0pp	67.1%+2.0pp	65.1%-1.5pp	66.6%+1.0pp	65.6%-0.6pp	66.1%-0.9pp	67.0%
Operating Margin	20.3%+15.8pp	4.5%-8.5pp	13.0%+2.7pp	10.3%-11.9pp	22.3%-0.1pp	22.4%-1.2pp	23.6%-0.7pp	24.2%+1.0pp	23.3%-37.9pp	61.2%+42.1pp	19.1%+1.4pp	17.6%+3.1pp	14.6%-2.7pp	17.3%-2.4pp	19.7%
Net Margin	-9.9%+11.9pp	-21.9%-28.2pp	6.4%-0.7pp	7.0%-11.5pp	18.5%-2.5pp	21.0%+0.1pp	20.9%-1.6pp	22.6%+6.8pp	15.8%-27.8pp	43.6%+30.4pp	13.2%+0.9pp	12.4%+1.7pp	10.7%-2.0pp	12.6%-1.9pp	14.5%
Return on Equity	-21.0%+8.0pp	-29.0%-35.0pp	6.0%-4.8pp	10.7%-4.1pp	14.8%-2.3pp	17.1%+0.3pp	16.8%-3.2pp	20.0%+2.7pp	17.2%-38.3pp	55.5%+25.3pp	30.3%+6.6pp	23.7%+5.8pp	17.9%-4.9pp	22.8%-0.2pp	23.0%
Return on Assets	-8.9%+2.7pp	-11.6%-14.3pp	2.7%-1.8pp	4.5%-7.7pp	12.2%-1.9pp	14.0%0.0pp	14.1%-2.7pp	16.8%+3.0pp	13.8%-24.1pp	37.9%+24.1pp	13.8%+1.0pp	12.8%-0.5pp	13.3%-3.3pp	16.6%-0.8pp	17.4%
Current Ratio	2.49+0.5x	1.98-0.2x	2.19+0.1x	2.08-2.5x	4.63-0.1x	4.71-1.1x	5.78+0.4x	5.39+1.1x	4.32+2.0x	2.300.0x	2.26-0.1x	2.40-0.2x	2.62+0.2x	2.45-1.0x	3.46
Debt-to-Equity	0.720.0x	0.680.0x	0.64-0.1x	0.70+0.7x	0.00-0.2x	0.220.0x	0.200.0x	0.19-0.1x	0.25+0.3x	0.00-0.7x	0.67+0.3x	0.41+0.4x	0.00-0.4x	0.36+0.1x	0.31
Asset Turnover	0.90+0.4x	0.53+0.1x	0.42-0.2x	0.630.0x	0.660.0x	0.670.0x	0.67-0.1x	0.74-0.1x	0.870.0x	0.87-0.2x	1.050.0x	1.04-0.2x	1.25-0.1x	1.32+0.1x	1.20
FCF Margin	13.0%+0.4pp	12.6%+8.2pp	4.4%+5.5pp	-1.1%-20.5pp	19.3%+7.2pp	12.1%-4.2pp	16.3%-9.6pp	25.9%+24.3pp	1.6%-54.5pp	56.0%+45.4pp	10.6%+7.1pp	3.5%-4.9pp	8.3%-4.8pp	13.1%-3.7pp	16.8%

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Gross Margin	62.1%-0.8pp	60.0%+14.3pp	62.1%+0.3pp	62.9%+2.6pp	62.9%+2.1pp	45.7%	61.8%+12.8pp	60.3%+11.7pp
Operating Margin	19.2%-1.8pp	20.3%+39.4pp	22.5%+11.4pp	17.4%+5.2pp	21.0%+5.3pp	-19.1%	11.1%+5.9pp	12.2%+5.7pp
Net Margin	14.1%+60.0pp	16.6%+111.5pp	-27.0%-29.9pp	13.8%+9.2pp	-45.9%-51.5pp	-94.9%	2.9%+0.6pp	4.7%+1.2pp
Return on Equity	7.2%+25.3pp	9.5%+42.7pp	-12.4%-13.1pp	4.9%+3.8pp	-18.0%-19.4pp	-33.2%	0.7%-0.2pp	1.2%0.0pp
Return on Assets	3.5%+10.9pp	4.0%+17.3pp	-5.5%-5.8pp	2.1%+1.6pp	-7.4%-8.1pp	-13.3%	0.3%0.0pp	0.5%0.0pp
Current Ratio	2.68+0.5x	2.49+0.5x	2.84+0.8x	2.14+0.1x	2.17-0.1x	1.98-0.2x	2.01-0.1x	2.090.0x
Debt-to-Equity	0.56-0.1x	0.720.0x	0.69+0.2x	0.570.0x	0.67+0.1x	0.680.0x	0.50-0.2x	0.55-0.1x
Asset Turnover	0.25+0.1x	0.24+0.1x	0.20+0.1x	0.150.0x	0.160.0x	0.14	0.110.0x	0.120.0x
FCF Margin	10.2%+2.5pp	13.0%+0.9pp	13.7%+7.8pp	17.7%-2.9pp	7.7%-4.0pp	12.0%	5.9%+10.1pp	20.6%+18.1pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Masimo Corporation MASI	FY2025	$1.5B	-$151.5M	-9.9%	$9.4B	66/100
GLOBUS MEDICAL INC GMED	FY2025	$2.9B	$537.9M	18.3%	$10.0B	77/100
Bio-Rad Laboratories, Inc. BIO	FY2025	$2.6B	$759.9M	29.4%	$9.8B	52/100
iRhythm Holdings, Inc. IRTC	FY2025	$747.1M	-$45.0M	-6.0%	$3.5B	43/100
Glaukos Corporation GKOS	FY2025	$507.4M	-$187.7M	-37.0%	$9.8B	51/100
Bruker Corporation BRKR	FY2025	$3.4B	-$8.3M	-0.2%	$9.0B	44/100

Where Masimo Corporation Ranks

Frequently Asked Questions

What is Masimo Corporation's annual revenue?

Masimo Corporation (MASI) reported $1.5B in total revenue for fiscal year 2025. This represents a 9.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Masimo Corporation's revenue growing?

Masimo Corporation (MASI) revenue grew by 9.4% year-over-year, from $1.4B to $1.5B in fiscal year 2025.

Is Masimo Corporation profitable?

No, Masimo Corporation (MASI) reported a net income of -$151.5M in fiscal year 2025, with a net profit margin of -9.9%.

What is Masimo Corporation's EBITDA?

Masimo Corporation (MASI) had EBITDA of $348.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Masimo Corporation have?

As of fiscal year 2025, Masimo Corporation (MASI) had $152.3M in cash and equivalents against $518.0M in long-term debt.

What is Masimo Corporation's gross margin?

Masimo Corporation (MASI) had a gross margin of 61.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Masimo Corporation's operating margin?

Masimo Corporation (MASI) had an operating margin of 20.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Masimo Corporation's net profit margin?

Masimo Corporation (MASI) had a net profit margin of -9.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Masimo Corporation's return on equity (ROE)?

Masimo Corporation (MASI) has a return on equity of -21.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Masimo Corporation's free cash flow?

Masimo Corporation (MASI) generated $198.4M in free cash flow during fiscal year 2025. This represents a 13.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Masimo Corporation's operating cash flow?

Masimo Corporation (MASI) generated $217.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Masimo Corporation's total assets?

Masimo Corporation (MASI) had $1.7B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Masimo Corporation's capital expenditures?

Masimo Corporation (MASI) invested $19.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Masimo Corporation spend on research and development?

Masimo Corporation (MASI) invested $126.4M in research and development during fiscal year 2025.

Does Masimo Corporation buy back shares?

Yes, Masimo Corporation (MASI) spent $363.7M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Masimo Corporation have outstanding?

Masimo Corporation (MASI) had 52M shares outstanding as of fiscal year 2025.

What is Masimo Corporation's current ratio?

Masimo Corporation (MASI) had a current ratio of 2.49 as of fiscal year 2025, which is generally considered healthy.

What is Masimo Corporation's debt-to-equity ratio?

Masimo Corporation (MASI) had a debt-to-equity ratio of 0.72 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Masimo Corporation's return on assets (ROA)?

Masimo Corporation (MASI) had a return on assets of -8.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Masimo Corporation's Altman Z-Score?

Masimo Corporation (MASI) has an Altman Z-Score of 8.78, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Masimo Corporation's Piotroski F-Score?

Masimo Corporation (MASI) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Masimo Corporation's earnings high quality?

Masimo Corporation (MASI) reported a net loss of $151.5M while generating $217.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Masimo Corporation cover its interest payments?

Masimo Corporation (MASI) has an interest coverage ratio of 9.34x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Masimo Corporation?

Masimo Corporation (MASI) scores 66 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.